The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Latest Developments in Imaging of Fibroblast Activation Protein
Open accessAbstract
Fibroblast activation protein (FAP), a membrane-anchored peptidase, is highly expressed in cancer-associated fibroblasts in more than 90% of epithelial tumors and contributes to progression and worse prognosis of different cancers. Therefore, FAP is considered a promising target for radionuclide-based approaches for diagnosis and treatment of tumors and for the diagnosis of nonmalignant diseases associated with a remodeling of the extracellular matrix. Accordingly, a variety of quinolone-based FAP inhibitors (FAPIs) coupled to chelators were developed displaying specific binding to human and murine FAP with a rapid and almost complete internalization. Because of a high tumor uptake and a very low accumulation in normal tissues, as well as a rapid clearance from the circulation, a high contrast is obtained for FAPI PET/CT imaging even at 10 min after tracer administration. Moreover, FAPI PET/CT provides advantages over 18F-FDG PET/CT in several tumor entities for initial staging and detection of tumor recurrence and metastases, including peritonitis carcinomatosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H., Röhrich, M., Winter, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227967 · Cited by 1,464
Self-citationLindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
Self-citationA Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Loktev, A., Lindner, T., Mier, W., Debus, J., Altmann, A., Jäger, D., Giesel, F., Kratochwil, C., Barthe, P., Roumestand, C., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210435 · Cited by 777
Self-citationTumor-associated stromal cells as key contributors to the tumor microenvironment
Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., & Marini, F. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0740-2 · Cited by 746 · cited 1×
“Notably, through the production of various growth factors, chemokines, and cytokines, noncancerous stromal cells promote extracellular matrix remodeling, induction of angiogenesis, cellular migration, drug resistance, and evasion of immunosurveillance, facilitating invasion and the development of metastasis (2).”
BackgroundGiesel, F. L., Kratochwil, C., Lindner, T., Marschalek, M. M., Loktev, A., Lehnert, W., Debus, J., Jäger, D., Flechsig, P., Altmann, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215913 · Cited by 740
Self-citationCarcinoma-associated fibroblasts: orchestrating the composition of malignancy
Gascard, P., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 732
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 1×
“Moreover, the combination of FAP vaccination and chemotherapy improved the antitumor response in murine CT26 colon carcinoma and D2F2 breast cancer models (29).”
BackgroundScanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., & Rettig, W. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5657 · Cited by 574
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 554
Self-citationChen, H., Pang, Y., Wu, J., Zhao, L., Hao, B., Wu, J., Wei, J., Wu, S., Zhao, L., Luo, Z., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04769-z · Cited by 545
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer
Henry, L. R., Lee, H.-O., Lee, J. S., Klein-Szanto, A., Watts, P., Ross, E. A., Chen, W.-T., & Cheng, J. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1746 · Cited by 364
Targeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Bu, L., Baba, H., Yoshida, N., Miyake, K., Yasuda, T., Uchihara, T., Tan, P., & Ishimoto, T. (2019) · Oncogene · doi:10.1038/s41388-019-0765-y · Cited by 329
Watabe, T., Liu, Y., Kaneda-Nakashima, K., Shirakami, Y., Lindner, T., Ooe, K., Toyoshima, A., Nagata, K., Shimosegawa, E., Haberkorn, U., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233122 · Cited by 302
Self-citationGiesel, F. L., Adeberg, S., Syed, M., Lindner, T., Jiménez-Franco, L. D., Mavriopoulou, E., Staudinger, F., Tonndorf-Martini, E., Regnery, S., Rieken, S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245084 · Cited by 302
Self-citationBrennen, W. N., Isaacs, J. T., & Denmeade, S. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0340 · Cited by 289
Jansen, K., Heirbaut, L., Verkerk, R., Cheng, J. D., Joossens, J., Cos, P., Maes, L., Lambeir, A.-M., De Meester, I., Augustyns, K., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500031w · Cited by 287
Narra, K., Mullins, S. R., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J., McKee, P. A., Egleston, B., Cohen, S. J., Weiner, L. M., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4874 · Cited by 275
Radiation Dosimetry and Biodistribution of 68 Ga-FAPI-46 PET Imaging in Cancer Patients
Meyer, C. A. L., Dahlbom, M. L., Lindner, T., Vauclin, S., Mona, C. E., Slavik, R., Czernin, J. G., Haberkorn, U., & Calais, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236786 · Cited by 262
Self-citationJansen, K., Heirbaut, L., Cheng, J. D., Joossens, J., Ryabtsova, O., Cos, P., Maes, L., Lambeir, A.-M., De Meester, I., Augustyns, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300410d · Cited by 260
Varasteh, Z., Mohanta, S., Robu, S., Braeuer, M., Li, Y., Omidvari, N., Topping, G., Sun, T., Nekolla, S. G., Richter, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226993 · Cited by 256
Self-citationEffective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts
Ostermann, E., Garin-Chesa, P., Heider, K. H., Kalat, M., Lamche, H., Puri, C., Kerjaschki, D., Rettig, W. J., & Adolf, G. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5211 · Cited by 246
Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma
Cohen, S. J., Alpaugh, R. K., Palazzo, I., Meropol, N. J., Rogatko, A., Xu, Z., Hoffman, J. P., Weiner, L. M., & Cheng, J. D. (2008) · Pancreas · doi:10.1097/mpa.0b013e31816618ce · Cited by 243
Tillmanns, J., Hoffmann, D., Habbaba, Y., Schmitto, J. D., Sedding, D., Fraccarollo, D., Galuppo, P., & Bauersachs, J. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.08.016 · Cited by 237
Liu, F., Qi, L., Liu, B., Liu, J., Zhang, H., Che, D., Cao, J., Shen, J., Geng, J., Bi, Y., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116683 · Cited by 227
Chen, H., Zhao, L., Ruan, D., Pang, Y., Hao, B., Dai, Y., Wu, X., Guo, W., Fan, C., Wu, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04940-6 · Cited by 221
Luo, Y., Pan, Q., Yang, H., Peng, L., Zhang, W., & Li, F. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244723 · Cited by 202
Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
Lindner, T., Altmann, A., Krämer, S., Kleist, C., Loktev, A., Kratochwil, C., Giesel, F., Mier, W., Marme, F., Debus, J., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.239731 · Cited by 192
Self-citationDisentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
Schmidkonz, C., Rauber, S., Atzinger, A., Agarwal, R., Götz, T. I., Soare, A., Cordes, M., Prante, O., Bergmann, C., Kleyer, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217408 · Cited by 187
Self-citationKoerber, S. A., Staudinger, F., Kratochwil, C., Adeberg, S., Haefner, M. F., Ungerechts, G., Rathke, H. G., Winter, E., Lindner, T., Syed, M., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237016 · Cited by 168
Self-citationToms, J., Kogler, J., Maschauer, S., Daniel, C., Schmidkonz, C., Kuwert, T., & Prante, O. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242958 · Cited by 168
Ghersi, G., Zhao, Q., Salamone, M., Yeh, Y., Zucker, S., & Chen, W.-T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1245 · Cited by 166
Fibroblast Activation Protein in Remodeling Tissues
Jacob, M., Chang, L., & Pure, E. (2012) · Current Molecular Medicine · doi:10.2174/156652412803833607 · Cited by 164
Syed, M., Flechsig, P., Liermann, J., Windisch, P., Staudinger, F., Akbaba, S., Koerber, S. A., Freudlsperger, C., Plinkert, P. K., Debus, J., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04859-y · Cited by 164
Self-citationTargeting fibroblast activation protein in cancer ndash Prospects and caveats
Sedo, A. (2018) · Frontiers in Bioscience · doi:10.2741/4682 · Cited by 161
Zi, F., He, J., He, D., Li, Y., Li, Y., & Cai, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3197 · Cited by 158
Röhrich, M., Loktev, A., Wefers, A. K., Altmann, A., Paech, D., Adeberg, S., Windisch, P. Y., Hielscher, T., Flechsig, P., Floca, R. O., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04444-y · Cited by 153
Self-citationMolecular cloning of seprase: a serine integral membrane protease from human melanoma
Goldstein, L. A., Ghersi, G., Piñeiro-Sánchez, M. L., Salamone, M., Yeh, Y., Flessate, D., & Chen, W. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00032-x · Cited by 150
Shi, X., Xing, H., Yang, X., Fang, L., Yao, S., Zhang, H., Zhao, H., Hacker, M., Huo, L., & Li, X. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04882-z · Cited by 128
Moon, E. S., Elvas, F., Vliegen, G., Lombaerde, S. D., Vangestel, C., Bruycker, S. D., Bracke, A., Eppard, E., Greifenstein, L., Klasen, B., et al. (2020) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-020-00102-z · Cited by 122
Laverman, P., van der Geest, T., Terry, S. Y. A., Gerrits, D., Walgreen, B., Helsen, M. M. A., Nayak, T. K., Freimoser–Grundschober, A., Waldhauer, I., Hosse, R. J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152959 · Cited by 109
Nagaraju, C. K., Dries, E., Popović, N., Singh, A. A., Haemers, P., Roderick, H. L., Claus, P., Sipido, K. R., & Driesen, R. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-09790-1 · Cited by 95
Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
Eager, R., Cunningham, C. C., Senzer, N. N., Richards, D., Raju, R. N., Jones, B. N., Uprichard, M. J., & Nemunaitis, J. J. (2009) · Clinical Oncology · doi:10.1016/j.clon.2009.04.007 · Cited by 92
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Eager, R. M., Cunningham, C. C., Senzer, N. N., Stephenson, J., Anthony, S. P., O'Day, S. J., Frenette, G., Pavlick, A. C., Jones, B. N., Uprichard, M. J., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-263 · Cited by 91
Egger, C., Cannet, C., Gérard, C., Suply, T., Ksiazek, I., Jarman, E., & Beckmann, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.022 · Cited by 91
Ke, M., Chen, S., Peng, X.-H., Zheng, Q.-F., Zheng, B., Yeh, C., & Huang, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.056 · Cited by 76
Increased N‐terminal cleavage of alpha‐2‐antiplasmin in patients with liver cirrhosis
de Willige, S. U., Malfliet, J. J. M. C., Janssen, H. L. A., Leebeek, F. W. G., & Rijken, D. C. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12396 · Cited by 45
van der Geest, T., Laverman, P., Gerrits, D., Walgreen, B., Helsen, M. M. A., Klein, C., Nayak, T. K., Storm, G., Metselaar, J. M., Koenders, M. I., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177931 · Cited by 37
Cited by
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Yang, A.-T., Kim, Y.-O., Yan, X.-Z., Abe, H., Aslam, M., Park, K.-S., Zhao, X.-Y., Jia, J.-D., Klein, T., You, H., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.12.005 · Cited by 144
Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET/CT
Zheng, S., Lin, R., Chen, S., Zheng, J., Lin, Z., Zhang, Y., Xue, Q., Chen, Y., Zhang, J., Lin, K., et al. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01673-w · Cited by 62
Strating, E., Wassenaar, E., Verhagen, M., Rauwerdink, P., van Schelven, S., de Hingh, I., Rinkes, I. B., Boerma, D., Witkamp, A., Lacle, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01748-z · Cited by 36
“We identified fibroblast activation protein (FAP) as one such marker and provide proof-ofconcept in cancer patients that molecular imaging of FAP with the (68)Ga-DOTA-FAPI-46 PET tracer [16] is a promising strategy to quantify ‘CMS4 tumour load’ in CRC patients, and—possibly—to evaluate the response of these lesions t…”
BackgroundInfluentialMeng, Y., Zhang, H., Li, Q., Xing, P., Liu, F., Cao, K., Fang, X., Li, J., Yu, J., Feng, X., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27648 · Cited by 12
Metadata
- Authors
- Altmann, A., Haberkorn, U., & Siveke, J.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2020-10-30
- Volume
- 62
- Issue
- 2
- Pages
- 160-167
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W3095979138
- Cited by
- 257
- References
- 52
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.